Verrica Pharmaceuticals (VRCA) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.59 and quarterly revenue of $4.59M.

In the most recent quarter (Q4), Verrica Pharmaceuticals reported EPS of $-0.51, beating estimates of $-0.56 by 0.09%. Revenue came in at $5.09M, exceeding the estimate of $4.39M by 0.16%.

Verrica Pharmaceuticals has beaten EPS estimates in 5 consecutive quarters.

Over the last 4 quarters, Verrica Pharmaceuticals has averaged an EPS surprise of 0.74% and a revenue surprise of 0.61%.